Clinical Trial Update: A Study to Determine the Safety and Effectiveness of RAD001 (Everolimus) in Patients With Lymphangioleiomyomatosis [Phase 2]

View source ↗

Summary

Phase 2 clinical trial updating safety and effectiveness of everolimus (RAD001) in lymphangioleiomyomatosis (LAM).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lymphangioleiomyomatosis

Drugs mentioned

• Everolimus (everolimus)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Lymphangioleiomyomatosis | Phase 2 | Status: COMPLETED | Results posted: 2020-11-19